Analytical Data
-
Gene name
TNFSF13
- Application
-
Alternative Names
TNFSF13；APRIL；Tumor necrosis factor ligand superfamily member 13
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75888
-
Expression Region
105-250aa
-
AA Sequence
AVLTQKQKKQ HSVLHLVPIN ATSKDDSDVT VMWQPALRR GRGLQAQGYG VRIQDAGVYL LYSQVLFQDV TFTMGQVVSR EGQGRQETLF CIRSMPSHP DRAYNSCYSA GVFHLHQGDI LSVIIPRARA KLNLSPHGTF LGFVKL
-
Molecular Weight
20 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFSF13, also known as B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) superfamily that plays a critical role in B-cell survival, proliferation, and differentiation. Its significance in the immune system has garnered substantial research interest, particularly in understanding autoimmune diseases and lymphoid malignancies. Dysregulation of TNFSF13 has been implicated in various pathologies, including systemic lupus erythematosus (SLE) and multiple myeloma, where elevated levels of BAFF contribute to excessive B-cell activation and survival. Researchers have focused on the recombinant production of TNFSF13 to explore its structural properties, receptor interactions, and biological functions. This recombinant protein serves as a valuable tool in elucidating the underlying mechanisms of B-cell biology and the potential therapeutic avenues for targeting BAFF in autoimmune disorders. Furthermore, the generation of monoclonal antibodies against TNFSF13 has shown promise in treating conditions associated with its overexpression. Consequently, the study of TNFSF13 recombinant protein not only advances our fundamental understanding of immune regulation but also paves the way for innovative strategies to modulate immune responses in clinical settings.
